Holen Sie sich die Stockscreener-App
9.85
2.57%
-0.26
Handel nachbörslich:
10.04
0.19
+1.93%
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Can Fulcrum Therapeutics Inc. stock beat market expectations this quarterFootwear buying guidance for consistent weekly training mileage focuses on stable support and balance, making it a solid option for daily use. - ulpravda.ru
How Fulcrum Therapeutics Inc. stock performs in stagflation2025 Market Sentiment & Verified Entry Point Signals - ulpravda.ru
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Can Fulcrum Therapeutics Inc. stock surprise with earnings upside2025 Volume Leaders & Stock Timing and Entry Methods - ulpravda.ru
Will Fulcrum Therapeutics Inc. stock outperform Dow Jones indexWeekly Profit Report & Long-Term Capital Growth Strategies - ulpravda.ru
How geopolitical tensions affect Fulcrum Therapeutics Inc. stock2025 Biggest Moves & Pattern Based Trade Signal System - ulpravda.ru
Will Fulcrum Therapeutics Inc. stock benefit from AI adoptionPrice Action & Community Trade Idea Sharing Platform - ulpravda.ru
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: A Biotech With A 90% Upside Potential - DirectorsTalk Interviews
Why Fulcrum Therapeutics Inc. stock is a must watch in 2025Currency Fluctuation Impact & Consistent Triple Returns - ulpravda.ru
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
2026 world cup results breakdown: Is Fulcrum Therapeutics Inc. stock supported by strong cash flows2026 world cup usa national team round of 32 playmakers pressing system odds analysis expert opinion - ulpravda.ru
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Decrease in Short Interest - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.3%Time to Sell? - MarketBeat
Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet - Yahoo Finance
Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 3%Should You Buy? - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Fulcrum Therapeutics Earnings Notes - Trefis
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.7%Should You Sell? - MarketBeat
RBC Capital maintains Fulcrum Therapeutics (FULC) sector perform recommendation - MSN
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study - Insider Monkey
Fulcrum Therapeutics (FULC) Price Target Increased by 32.56% to 19.38 - Nasdaq
Retail Trends: Why Fulcrum Therapeutics Inc stock is a must watch in 20252025 Investor Takeaways & High Yield Stock Recommendations - moha.gov.vn
FULC (Fulcrum Therapeutics) Price-to-Tangible-Book : 3.35 (As of Dec. 20, 2025) - GuruFocus
What makes Fulcrum Therapeutics Inc. stock attractive to growth fundsJuly 2025 Selloffs & Safe Entry Point Alerts - Улправда
Why Fulcrum Therapeutics Inc. stock is considered a top pick2025 Retail Activity & Free Technical Pattern Based Buy Signals - Улправда
Is Fulcrum Therapeutics Inc. stock undervalued vs historical averages2025 Performance Recap & Community Driven Trade Alerts - Улправда
Retail Trends: Why Fulcrum Therapeutics Inc. stock is a must watch in 2025 - Улправда
Published on: 2025-12-19 18:03:13 - DonanımHaber
Can Fulcrum Therapeutics Inc. stock deliver consistent earnings growthQuarterly Performance Summary & High Win Rate Trade Tips - DonanımHaber
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Market Trends: Will Fulcrum Therapeutics Inc. stock attract more institutional investorsWeekly Investment Report & Technical Entry and Exit Tips - Улправда
Insider Sell: Curtis Oltmans Sells Shares of Fulcrum Therapeutics Inc (FULC) - GuruFocus
Fulcrum Therapeutics Chief Legal Officer Sells Shares - TradingView — Track All Markets
B of A Securities maintains Fulcrum Therapeutics (FULC) underperform recommendation - MSN
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Hold at Wall Street Zen - MarketBeat
Firmware Signing Platform Market Size to Reach USD 6.29 Billion by 2033 | Report by SNS Insider - GlobeNewswire Inc.
Ra Capital Management, L.P. Sells 4,175,139 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.7% on Insider Selling - Defense World
Truist Financial Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC) - The Globe and Mail
Truist Securities Maintains Fulcrum Therapeutics (FULC) Buy Recommendation - Nasdaq
Truist Securities raises Fulcrum Therapeutics stock price target on positive sickle cell data - ca.investing.com
FULC: Truist Securities Raises Price Target for Fulcrum Therapeu - GuruFocus
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 5.7% After Insider Selling - MarketBeat
Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants - MSN
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
Fulcrum shares jump 50% after early PIONEER trial data impress in sickle cell disease - MSN
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million By Investing.com - Investing.com Nigeria
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million - Investing.com
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):